Takeda has teamed up with Cognition Kit to trial the use of an Apple Watch app to monitor people with depression.

Aveo inches closer to completing a crucial trial of its main asset tivozanib—almost four years after the FDA turned down the kidney cancer drug.

Just 12 months ago, Incyte was hit with a major trial setback when its JAK inhibition drug for solid tumors flopped a key test. Since then the biotech has been…

Cyclacel has learnt sapacitabine is no better at improving overall survival in elderly patients with AML than decitabine, triggering a 30% stock drop.

Editors at The BMJ have warned that President Trump’s policies could damage biomedical research and regulation around the world.

Immunexpress earned 510(k) clearance for its RNA-based clinical diagnostic that detects sepsis in critically ill patients. The test, which uses whole blood,…

Celiacs could be freed from the gluten-free aisle of the supermarket if a therapeutic approach developed by ImmusanT proves effective in trials.

Argos' cancer vaccine candidate failed a phase 3 futility analysis, wiping 65% off its stock.

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Topspin Biotech Fund (…